Telomir Pharmaceuticals, Inc. Common Stock (TELO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $36.15M
Last updated: Nov 17, 2026 at 11:04 AM ET
Telomir Pharmaceuticals, Inc. Common Stock (TELO) Financials: Revenue, Profit and Cash Flow
Telomir Pharmaceuticals, Inc. Common Stock reported revenue of $0 for the fiscal year ended Sep 30, 2025. That year, net income was -$10.41M, operating cash flow was -$3.69M and free cash flow was -$3.69M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$705.23K.
Revenue and Margins
The company reported no revenue in the fiscal year ended Sep 2025, with an operating loss of $10.54M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Sep 2025 | $0 | N/A | N/A | N/A | N/A |
| Sep 2024 | $0 | N/A | N/A | N/A | N/A |
| Sep 2023 | $0 | N/A | N/A | N/A | N/A |
| Sep 2022 | $0 | N/A | N/A | N/A | N/A |
| Sep 2021 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Sep 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|
| Cost of revenue | N/A | N/A | $3.94M | N/A | N/A |
| Gross profit | N/A | N/A | -$3.94M | N/A | N/A |
| Research and development | $2.44M | $2.24M | $1.57M | $833.21K | $126.49K |
| Operating income | -$10.54M | -$12.24M | -$3.94M | -$854.15K | -$138.13K |
| Net income | -$10.41M | -$16.53M | -$13.07M | -$854.15K | -$138.13K |
| EBITDA | -$10.41M | -$7.86M | N/A | -$854.15K | -$138.13K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $18.79M | $0 | $0 | $0 | $0 |
| Gross profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $9.40M | -$6.01M | -$1.47M | -$1.92M | N/A |
| Operating income | -$745.20K | -$1.76M | -$1.04M | -$2.13M | -$1.15M | -$5.07M | -$2.19M | -$2.91M | -$6.01M | -$1.47M | -$1.92M | -$1.08M |
| Net income | -$705.23K | -$1.72M | -$990.95K | -$2.06M | -$1.10M | -$5.07M | -$2.18M | -$2.90M | -$5.99M | -$1.45M | -$6.25M | -$9.33M |
Balance Sheet
As of Sep 2025, cash and equivalents exceeded short-term debt of $473.75K by $6.81M.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|
| Total assets | $7.34M | $1.32M | $4.77M | $48.73K | $55.00K |
| Current assets | $7.34M | $1.32M | $435.23K | $1.42K | $0 |
| Cash and equivalents | $7.29M | $1.27M | $1.23K | $1.42K | $0 |
| Total liabilities | $1.43M | $680.97K | $1.34M | $986.01K | $138.13K |
| Short-term debt | $473.75K | $93.43K | $101.00K | $581.79K | $119.40K |
| Shareholder equity | $5.91M | $643.04K | $3.44M | -$937.28K | -$83.13K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $4.64M | $5.37M | $5.79M | $7.34M | $7.40M | $829.61K | $491.19K | $1.32M | $1.04M | $2.10M | $3.50M | $4.77M |
| Total liabilities | $236.75K | $332.42K | $827.31K | $1.43M | $422.81K | $348.39K | $652.29K | $680.97K | $599.91K | $534.15K | $486.55K | $1.34M |
| Cash and equivalents | $4.52M | $5.17M | $5.56M | $7.29M | $7.33M | $754.32K | $403.00K | $1.27M | $834.64K | $1.88M | $3.27M | $1.23K |
| Shareholder equity | $4.40M | $5.03M | $4.96M | $5.91M | $6.98M | $481.22K | -$161.11K | $643.04K | $442.07K | $1.57M | $3.02M | $3.44M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Sep 2025.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$3.69M | -$5.07M | -$3.86M | -$468.66K | -$119.40K |
| Capital expenditures | $0 | $0 | $4 | $0 | $4 |
| Free cash flow | -$3.69M | -$5.07M | -$3.86M | -$468.66K | -$119.40K |
| Financing cash flow | $9.71M | $6.34M | $3.86M | $470.08K | $119.40K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$586.44K | -$1.01M | -$1.77M | -$1.20M | -$927.26K | -$696.45K | -$863.13K | -$605.81K | -$1.00M | -$1.52M | -$1.94M | -$1.09M |
| Capital expenditures | $0 | $0 | $0 | $3 | $5 | $4 | $0 | $2 | $0 | $0 | $5 | $5 |
| Free cash flow | -$586.44K | -$1.01M | -$1.77M | -$1.20M | -$927.27K | -$696.45K | -$863.13K | -$605.81K | -$1.00M | -$1.52M | -$1.94M | -$1.09M |
Frequently Asked Questions About TELO
What is Telomir Pharmaceuticals, Inc. Common Stock's annual revenue?
Telomir Pharmaceuticals, Inc. Common Stock reported revenue of $0 for the fiscal year ended Sep 30, 2025.
Is Telomir Pharmaceuticals, Inc. Common Stock profitable?
No. Telomir Pharmaceuticals, Inc. Common Stock reported net income of -$10.41M for the fiscal year ended Sep 30, 2025.
How much free cash flow does TELO generate?
For the fiscal year ended Sep 30, 2025, operating cash flow of -$3.69M minus capital expenditures of $0 produced free cash flow of -$3.69M.
How much debt does Telomir Pharmaceuticals, Inc. Common Stock have?
The balance sheet dated Sep 30, 2025 reported short-term debt of $473.75K and cash and equivalents of $7.29M.
TELO pages: Overview, Forecast, Financials, Competitors